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Abstract
Background: A major impediment to the treatment of TB is a diagnostic process that requires multiple visits.
Descriptions of patient costs associated with diagnosis use different protocols and are not comparable.
Methods: We aimed to describe the direct costs incurred by adults attending TB diagnostic centres in four countries
and factors associated with expenditure for diagnosis. Surveys of 2225 adults attending smear-microscopy centres in
Nigeria, Nepal, Ethiopia and Yemen. Adults >18 years with cough >2 weeks were enrolled prospectively. Direct costs
were quantified using structured questionnaires. Patients with costs >75th quartile were considered to have high
expenditure (cases) and compared with patients with costs <75th quartile to identify factors associated with
high expenditure.
Results: The most significant expenses were due to clinic fees and transport. Most participants attended the centres
with companions. High expenditure was associated with attending with company, residing in rural areas/other towns
and illiteracy.
Conclusions: The costs incurred by patients are substantial and share common patterns across countries. Removing
user fees, transparent charging policies and reimbursing clinic expenses would reduce the poverty-inducing effects of
direct diagnostic costs. In locations with limited resources, support could be prioritised for those most at risk of high
expenditure; those who are illiterate, attend the service with company and rural residents.
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Background
TB is a disease of poverty mostly affecting populations
with limited resources and restricted access to health
services in low and middle income countries (LMICs).
For this reason the WHO has included a specific finan-
cial risk protection target in the new End TB Strategy
[1], that no TB affected household should experience
catastrophic costs due to TB [2].
Access to services is also a major problem. Of the
9.5 million incident cases estimated by the WHO in
2013, only 6 million were reported and the rest were
either not diagnosed, or diagnosed but not reported to
national TB programmes (NTPs) [3]. Over 77 million
smear investigations are conducted every year in the top
twenty high burden countries, most of these in poor
people [4]. Although drugs for first-line treatment for TB
are provided for free by most NTPs [5], the financial costs
incurred by the patient and their family for diagnosis re-
main significant [6, 7] and further costs may include hos-
pitalisation, treatment of side effects, nutrition and others.
The onset of disease often exacerbates poverty, as the
patient enters a lengthy period of expenditure on
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healthcare and productivity losses [8]. Direct costs start
with the patient undertaking consultations to reach a
diagnosis; yet these costs had been overlooked by policy-
makers until recently [1, 9]. Although TB diagnostics
tests are free of charge in most countries, public health
services often charge patients for their initial clinical
consultation, non-specific medications and other diagnos-
tic tests, such as x-rays [10, 11]. Patients must also meet
the cost of displacement from home, including domestic
responsibilities, subsistence and loss of earnings. Costs are
augmented by the need for patients to spend several days
near the health facility to complete the tests and meet
health staff for clinical management decisions [12, 13].
The cost of diagnosis is not uniform for all patients
and some have higher expenses than others. Identifying
individuals at risk of unusually high expenditure would
be of value to health programmes and policy makers to
inform the development of interventions to support pa-
tients with limited resources and high expenditure. Few
studies have isolated the patients’ direct and indirect
costs of attending NTP health facilities for diagnosis and
even fewer have compared expense patterns across
countries.
This study examined the direct financial costs incurred
by adults attending smear-microscopy based TB diag-
nostic centres in Ethiopia, Nepal, Nigeria and Yemen
and the risk factors for high expenditure for diagnosis.
This information was used to identify the population
groups that are more likely to experience higher costs to
undergo the TB diagnostic process.
Methods
Ethical approvals for the study were obtained from the
research ethics committees of the Liverpool School of
Tropical Medicine, the Institutional Review Boards of
the World Health Organisation and all the participating
institutions in Ethiopia, Nepal, Nigeria, and Yemen. All
participants gave written informed consent.
The study comprised four cross-sectional surveys
using the same study protocol among patients undergo-
ing routine smear microscopy in Ethiopia, Nepal, Nigeria
and Yemen [14]. These countries were selected because
the team was conducting a multi-country study to
optimise the use of smear microscopy and represented
high burden countries across three World Health
Organization regions [14]. Adults over 18 years with
chronic cough of more than 2 weeks duration attending
selected health facilities were invited to participate.
Participants were selected using systematic random
sampling, with a maximum of 10 patients interviewed
each day. In Ethiopia, participants were enrolled in
Bushullo Major Health Centre, a not-for-profit mission
hospital located in the outskirts of Hawassa; capital of
the Southern Region; in Nepal, patients were enrolled at
Tribhuvan University Teaching Hospital, a governmental
referral hospital in Kathmandu; in Abuja Nigeria, pa-
tients were enrolled in Wuse District Hospital, a govern-
ment general hospital and in Yemen, patients were
selected from the National Tuberculosis Institute (NTI),
a government referral centre and the main centre for the
diagnosis of TB in Sana’a. These centres were selected as
they were integral to the NTP services and large num-
bers of patients received a diagnosis of TB. The approxi-
mate number of patients routinely screened for TB in
each centre was 260, 1000, 250 and 780 per month in
Ethiopia, Nepal, Nigeria and Yemen, respectively. Individ-
uals attending the centres self-referred or were referred by
government, private or informal health care providers. A
minimum of 500 patients were expected to be recruited
from each study site to obtain a representative sample of
patients attending the centre and to have at least 80 %
power to identify risk factors with an Odds Ratio > 1.5.
Participants were interviewed using standard question-
naires to obtain demographic and clinical information,
to establish whether they had travelled with company
and the direct costs associated with attending the centre.
The questionnaire was structured and administered face
to face. Variables were defined using quantitative scales.
The questionnaire had been developed over several studies
preceding the study and developed jointly by all co-authors
to allow for local sensitivities and pooling of expertise.
Questionnaires were administered by local research staff
specifically trained and employed for the study, using the
local languages and took about 30 min per patient. Partici-
pants who were illiterate were supported by local staff to
clarify the questions and to estimate costs. Very few pa-
tients refused to participate, and >95 % of patients con-
sented on first approach. Patients who refused often did
because they were in a hurry or (in some settings) they pre-
ferred to be interviewed with a partner who was not
present at the time of the interview. A pilot study was run
in all countries before the main surveys and questions were
adjusted as needed. Direct costs were defined as medical
(clinic fees or registration costs, cost of investigation or
consultation, diagnostic tests and medication) and the costs
of transportation, food and accommodation for patient and
companion/s). Direct costs also included travel, overnight
stays, expenditure needed to attend the second day of diag-
nosis and others related to the current visit. Indirect costs,
defined as the loss of income for patient and household
due to lost work days, incapacity to work or forced chan-
ged of occupation and substitution costs (the cost of re-
placing the patient in their duties) and costs for previous
health service encounters were not measured.
Data were entered in a database using Epi-Info. The
participants’ characteristics by country were described
using summary statistics. Proportions were compared
using chi square tests and means were compared using
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parametric and non-parametric tests for normal and
skewed data, respectively. Costs were described using
quartiles and expressed as the median and 25–75th inter-
quartile range (25–75 % IQR). Costs were calculated by
adding the figures in the local currencies for each day of
attendance and converting the day’s total to US dollars
using the exchange rate at the beginning of the study.
Median expenditures were described stratified by se-
lected patient characteristics (e.g. rural/urban residency)
and compared using non parametric tests. Patients with
costs >75th quartile were considered to have high ex-
penditure (cases) and were compared with patients with
costs <75th quartile, to identify factors associated with
high expenditure. Odds Ratios (OR) with 95 % confi-
dence intervals (95%CI) were calculated and variables
with p values <0.2 were entered into backward and
forward logistic regressions to identify factors inde-
pendently associated with high expenditure (Adjusted
OR, AOR).
Results and discussion
A total of 2225 patients were enrolled, of whom 504
were enrolled in Ethiopia, 619 in Nepal, 502 in Nigeria
and 600 in Yemen. Patients had a mean (SD) age of 39
(17) years and were more likely to be male than female
in all countries except Nigeria (Table 1). The majority of
patients (67 %) were married or had partners; 27 % were
single and few were widowed (5 %) or divorced/
separated (2 %). Between 10 % (Nepal) and 47 % (Yemen)
of patients resided in rural areas and the majority of urban
patients resided in the town where the study health centre
was located; except in Nepal, where almost half of the pa-
tients from urban areas came from other cities. The mean
(SD) number of residents per household was 6.1 (4), ran-
ging from 4.1 (3) in Nigeria to 8.6 (5) in Yemen.
The majority of patients were accompanied by another
person in all countries except Nigeria, as shown in
Table 2. The accompanying person was a relative other
than the spouse in 77 % of patients, the spouse in 15 %
and 8 % were accompanied by other people. Few pa-
tients walked to the clinics and the most common trans-
port methods were buses in Nigeria, Nepal and Ethiopia
and cars or taxis in Yemen. Horse cart and motorbike
travel were also common in Ethiopia (26 %) and Nepal
(17 %), respectively. The median (25–75 % IQR) travel
time to the health centre was 40 (20–66) minutes. Travel
time was shortest in Nepal (25; 15–30 min) and longest
in Yemen (60, 30–150 min). The majority of patients
intended to spend the night at home the first day of con-
sultation (66 %), except in Nepal where 46 % planned to
stay with a relative. Very few patients paid for hotel ac-
commodation. Transport patterns for the second day of
consultation where similar, except in Yemen where pa-
tients realised that there was a low cost taxi service and
a lower number decided to travel by private car the
second day (data not shown).
Table 1 Patients’ demographic characteristics by country
Variablesa Ethiopia N = 504 Nepal N = 619 Nigeria N = 502 Yemen N = 600 All N = 2225
Age (Mean, ±SD) 33.2 (14.5) 43.8 (17.8) 34.4 (11) 41.8 (18.3) 38.7 (16.6)
Gender male: female (% male) 279: 225 (55.4) 395: 224 (63.8) 241: 258 (48.0) 329: 271 (54.8) 1244: 978 (55.9)
Marital status Single 176 (34.9) 107 (17.3) 183 (36.5) 124 (20.7) 590 (26.5)
With partner/married 302 (59.9) 507 (81.9) 259 (51.6) 426 (71) 1494 (67.1)
Divorced/separated 12 (2.4) 0 (0) 13 (2.6) 10 (1.7) 35 (1.6)
Widowed 14 (2.8) 5 (0.8) 44 (8.8) 40 (6.7) 103 (4.6)
Residence Rural 182 (36.1) 63 (10.2) 82 (16.3) 279 (46.5) 606 (27.2)
Same town 216 (42.9) 284 (45.9) 410 (81.7) 268 (44.7) 1178 (52.9)
Other town 106 (21) 272 (43.9) 7 (1.4) 53 (8.8) 438 (19.7)
Literate: Illiterate (% literate) 247: 257 (49) 475: 137 (76.7) 439: 57 (87.5) 264: 336 (44.0) 1425: 787 (64)
Education Nil 257 (51) 197 (31.8) 41 (8.2) 311 (51.8) 806 (36.2)
Primary incomplete 117 (23.2) 37 (6) 42 (8.4) 126 (21) 322 (14.5)
Primary complete 43 (8.5) 105 (17) 63 (12.5) 56 (9.3) 267 (12)
Secondary 62 (12.3) 127 (20.5) 220 (43.8) 61 (10.2) 470 (21.1)
Tertiary 24 (4.8) 153 (24.7) 133 (26.5) 46 (7.7) 356 (16)
Missing 1 (0.2) 0 (0) 3 (0.6) 0 (0) 4 (0.2)
Working: not working (% working) 235: 269 (46.6) 202: 417 (32.6) 368: 131 (73.3) 164: 436 (27.3) 969: 1253 (43.6)
Mean (SD) residents in household 5.7 (2.9) 5.5 (3) 4.1 (3) 8.6 (5) 6.1 (4)
aData represent frequency (%), unless otherwise specified. Sex, residency, marital and work status were missing for 3 patients and literacy for 13 patients
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Costs of attending the clinic
Costs associated with the two-day clinic attendance are
summarised in Table 3. Second day expenses were simi-
lar to first day expenses. The median costs were higher
in Yemen ($11.89) and Nepal ($8.22) and lower in
Nigeria ($5) and Ethiopia ($1.47). The most significant
expenses were due to the clinic costs (except Nigeria)
and transport. Miscellaneous expenses were frequently
reported in Nepal (83 % of patients) and were rare in
Yemen (12 %), Nigeria (3 %) and Ethiopia (0 %). Al-
though rare in Yemen, these expenses were significant.
Very few patients paid for overnight accommodation in
all countries and the median (25 % & 75 % IQR) expend-
iture was 0 in all countries.
The costs of attending the clinic stratified by the pa-
tients’ characteristics are described in Table 4. Older pa-
tients, those attending the clinic with company, residing
in rural areas or coming from other towns and patients
not working, had higher median costs than younger pa-
tients, those attending alone, residing in the same town
or working. Farmers, students and housewives had higher
median costs than patients with other occupations. Pa-
tients with a confirmed TB diagnosis (smear and culture
positive) had higher costs than patients without laboratory
Table 2 Characteristics of patients attending the clinics
Variablesa Ethiopia N = 504 Nepal N = 619 Nigeria N = 502 Yemen N = 600 All N = 2225
Alone: With company (% accompanied) 129:373 (74) 181:435 (70.3) 320:177 (35.3) 91:509 (84.8) 721:1494 (67.1)
Accompanying person Spouse 61 (16.4) 62 (14.3) 50 (28.2) 51 (10) 224 (15)
Other relative 276 (74) 336 (77.2) 94 (53.1) 439 (86.2) 1145 (76.6)
Friend 13 (3.5) 17 (3.9) 19 (10.7) 17 (3.3) 66 (4.4)
Neighbour 7 (1.9) 10 (2.3) 1 (0.6) 0 (0) 18 (1.2)
Other 16 (4.3) 9 (2.1) 13 (7.3) 2 (0.4) 40 (2.7)
Travel time, median (25–75 IQR), min 45 (27–120) 25 (15–30) 45 (30–60) 60 (30–150) 40 (20–66)
Transport day 1 Walking 67 (13.3) 92 (14.9) 12 (2.4) 12 (2) 183 (8.2)
Carried 6 (1.2) 0 (0) 2 (0.4) 0 (0) 8 (0.4)
Bicycle 14 (2.8) 7 (1.1) 0 (0) 0 (0) 21 (0.9)
Cart/horse 129 (25.6) 5 (0.8) 0 (0) 4 (0.7) 138 (6.2)
Motorbike 1 (0.2) 104 (16.8) 2 (0.4) 3 (0.5) 110 (4.9)
Bus 148 (29.4) 303 (48.9) 303 (60.4) 127 (21.2) 881 (39.6)
Car 33 (6.5) 14 (2.3) 76 (15.1) 203 (33.8) 326 (14.7)
Taxi 103 (20.4) 83 (13.4) 101 (20.1) 250 (41.7) 537 (24.1)
Other 1 (0.2) 8 (1.3) 1 (0.2) 1 (0.2) 11 (0.5)
Transport day 2 Walking 118 (23.4) 104 (16.8) 13 (2.6) 12 (2) 247 (11.1)
Carried 3 (0.6) 2 (0.3) 2 (0.4) 1 (0.2) 8 (0.4)
Bicycle 13 (2.6) 9 (1.5) 0 (0) 0 (0) 22 (1)
Cart/horse 181 (35.9) 5 (0.8) 0 (0) 5 (0.8) 191 (8.6)
Motorbike 1 (0.2) 104 (16.8) 1 (0.2) 3 (0.5) 109 (4.9)
Bus 44 (8.7) 298 (48.1) 309 (61.6) 143 (23.8) 794 (35.7)
Taxi 108 (21.4) 72 (11.6) 73 (14.5) 327 (54.5) 580 (26.1)
Other 5 (1) 9 (1.5) 38 (7.6) 0 (0) 52 (2.3)
Accommodation Home 358 (71) 267 (43.1) 437 (87.1) 407 (67.8) 1469 (66)
Relative 60 (11.9) 282 (45.6) 5 (1) 123 (20.5) 470 (21.1)
Hotel 66 (13.1) 40 (6.5) 0 (0) 68 (11.3) 174 (7.8)
Street 2 (0.4) 0 (0) 1 (0.2) 0 (0) 3 (0.1)
Shift 1 (0.2) 6 (1.0) 0 (0) 0 (0) 7 (0.3)
Hospital 15 (3.0) 20 (3.2) 54 (10.8) 2 (0.3) 91 (4.1)
aData are frequency (%), unless specified. Patients’ data missing for whether they attended with company (i10,) person accompanying (1), accommodation (11 and
transport (18). Min =minutes. P values for all comparisons between countries < 0.05, except for accompanying person being the spouse (p = 0.26) and Being
carried (p = 0.69)
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confirmation and expenses were similar among males and
females.
A total of 538 cases with expenditure >75th centile
(high expenditure) and 1679 patients with expend-
iture <75th centile (controls) were analysed. Factors asso-
ciated with high patient expenditure at the univariate and
multivariate analysis are shown in Table 5.
Although there were considerable differences be-
tween countries, residing in a rural area/other town
(OR (95 % CI) 23.6 (10.2–55); 1.5 (1.0–2.2) and 6.9 (4.2–
11.3), respectively), having low education (2.5 (1.3–4.8), 1.4
(1.0–2.1) and 1.9 (1.1–3.3), respectively) and attending with
company (19.7 (6.1, 63), 1.5 (1.0–2.2) and 3.4 (1.7–7.0), re-
spectively) were risk factors for high expenditure in
Ethiopia, Nepal and Yemen at the univariate level. Of
these, illiteracy (OR (95 % CI) 2.4 (1.4–4.3) and being
accompanied (OR (95 % CI) 2.7 (1.8–4.2) were also statis-
tically significant in Nigeria. Variables independently asso-
ciated with high expenditure in the multivariate analysis,
were attending the clinic with company (Ethiopia (AOR
7.5 (2.3–25.2), Yemen (AOR 3.1 (1.5–6.5) and Nigeria
(AOR 2.5 (1.6–3.9)), residing in rural areas and other
towns (Ethiopia (AOR 15.3 (6.5–36.0) and Yemen 6.7
(4.1–11.0)), illiteracy (Nigeria (AOR 1.9 (1.0–3.4) and
Nepal (AOR 2.5 (1.5–4.0)) and males with bacteriolo-
gically confirmed TB (Nepal, AOR 2.0 (1.3–3.2)).
Many illnesses are associated with poverty and individ-
uals often consider their financial position before attend-
ing health facilities. TB is no exception. As a disease of
poverty, TB is associated with many patients never at-
tending health services, attending late, or dropping out
after initiation of the diagnostic process [10, 15, 16]. As
TB diagnostic services are not available in all health
facilities, patients often express concerns about multiple
consultations, service fees, travel expenses and lost time
and opportunity costs [17]. This analysis confirms that
the direct costs sustained by patients undergoing a diag-
nosis of TB across multiple settings are substantial. A
large component of these are associated with clinic
costs, transport and patients attending the services with
company. According to the Multidimensional Poverty
Index, of the four countries Yemen, ranked as the least
poor at the time of the study, followed by Nigeria, Nepal
and Ethiopia [2]. Although it is difficult to compare
costs and expenditure directly between countries, as
living costs and income were very different across study
settings, our findings identified remarkable similarities.
Clinic user fees comprised a common and significant
cost. These fees are known to have a negative impact on
general health service utilisation and this is likely to be
more prominent in TB patients with limited financial
resilience [18]. Clinic costs for attending TB clinics in
the study comprised consultation fees, smear micros-
copy, X-rays and blood tests to screen for other diseases
[19]. Furthermore, although not captured in the study,
bacteriologically negative cases may undergo further
consultation and testing, pay for further visits and have
higher expenditure than smear-positive cases.
Although some NTPs retrospectively reimburse diag-
nostic costs to patients with TB, only 10–20 % of patients
receive a TB diagnosis. Patients therefore need to be pre-
pared to meet expenses up front; in practise 80–90 % will
not be reimbursed and these fees are likely to be a major
deterrent for attending diagnostic services. Furthermore,
we have documented elsewhere that patients are often
overcharged or pay under-the-counter fees to speed up
test results or to be seen earlier than others [20]. These
expenses are not documented in their receipts and where
Table 3 Median and IQR costs incurred for attending the clinic
Variablea Ethiopia ETB
N = 504
Nepal NPR
N = 619
Nigeria NGN
N = 502
Yemen YER
N = 600
Proportion reporting miscellaneous expenses, N (%)b 0 (0) 509 (82.6 %) 13 (2.6 %) 73 (12.2 %)
Clinic costs 8 (5; 8) 300 (300; 300) 0 (0; 150) 450 (250; 450)
Transport 16 (4; 36) 48 (0; 100) 400 (200; 600) 2000 (800; 3400)
Food 0 (0; 12) 0 (0; 0) 200 (0; 400) 0 (0; 400)
Overnight accommodation 0 (0; 0) 0 (0; 0) 0 (0; 0) 0 (0; 0)
Miscellaneous expenditure 0 (0; 0) 300 (200; 300) 500 (200; 1000) 1000 (500; 2000)
Total ETB 24 (11; 58) NPR 604 (500; 900) NGN 760 (420; 1400) YER 2550 (1400; 4850)
Total (US $) $1.47 $8.22 $5.00 $11.89
Proportion of poor/general population (H) using MPIc 0.900 0.647 0.635 0.525
Proportion of poor/general population < $1.25/dayd 0.390 0.551 0.644 0.175
Conversion rate to USD 1 = 0.061 1 = 0.013 1 = 0.007 1 = 0.005
aValues are medians and 25–75 % interquartile ranges (IQR) and given in the local currency, unless specified otherwise
bData missing for 10 patients (2 in Ethiopia, 3 in Nepal and 5 in Nigeria)
cFigures derived from the Multidimensional Poverty Index [34]
dProportion of people living on < $1.25/day, World Development Indicators, World Bank 2009
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reimbursement does occur, patients are often only par-
tially reimbursed.
Transport costs also contribute significantly to ex-
penditure in Ethiopia, Nigeria and Yemen, where a high
number of patients travel from other towns and rural
areas and use buses and taxis. In Ethiopia, the costs re-
flect the predominantly rural population of the country
and the cost of transport from areas with limited road
and public transport infrastructure. In Yemen, collective
public transport is limited to the main towns and
women often rely on private vehicles to attend the fairly
centralised diagnostic services. In Nigeria, buses were
very limited within the metropolitan areas of the Federal
Capital at the time of the study and people relied on
Table 4 Median costs incurred according to patients’ characteristics
Variablea Ethiopia N = 504 Nepal N = 619 Nigeria N = 502 Yemen N = 600
N ETB N NPR N NGN N YER
Age (years) <20 52 21 (8; 48) 37 600 (500; 740)*** 13 1100 (850; 2300)**** 54 2240 (1400; 3850)
20–49 367 24 (11; 58) 332 600 (500; 858) 444 725 (400; 1390) 312 2550 (1400; 4795)
≥50 83 26 (12; 60) 250 640 (560; 980) 40 800 (525; 1800) 232 2760 (1445; 5050)
Gender Male 278 24 (11; 56) 395 610 (500; 976) 241 700 (420; 1400) 328 2525 (1305; 4650)****
Female 224 24 (11: 60) 224 600 (500; 849) 256 800 (480; 1400) 271 2600 (1600; 5450)
Residency Rural 182 43 (24; 79)* 63 725 (460; 1890)* 82 700 (480; 1400) 279 3890 (2250; 6250)*
Same town 215 12 (5; 24) 284 598 (500; 749) 408 760 (400; 1400) 267 1650 (890; 2654)
Other town 105 56 (40; 82) 272 648 (572; 895) 7 1660 (850; 1800) 53 4250 (2450; 7360)
Companions Alone 129 9 (5; 14)* 181 600 (500; 750)** 320 645 (400; 1100)* 90 1420 (800; 2450)*
Accompanied 373 38 (24; 72) 435 620 (500; 980) 177 1100 (600; 1900) 509 2850 (1650; 5250)
Diagnosis Completed 488 24 (11; 58) 602 600 (500; 885) 423 750 (400; 1400) 569 2550 (1400; 4890)
$1.47 $8.16 $4.94 $11.89
Incomplete 14 27.5 (8; 48) 16 868 (400; 1188) 47 750 (500; 1400) 30 2675 (1650; 4050)
$1.68 $11.81 $4.94 $12.47
Smear result Positive 111 28 (13; 53) 71 700 (560; 1160)*** 85 800 (480; 1400) 120 2610 (1450; 4850)
Negative 389 24 (11; 58) 545 600 (500; 850) 403 740 (400; 1400) 476 2550 (1400; 4930)
Culture Positive 141 29 (13; 56)**** 73 672 (580; 1160)*** 80 770 (400; 1400) 150 2535 (1400; 4800)
Negative 345 24 (11; 58) 515 600 (500; 840) 399 760 (420; 1400) 430 2555 (1450; 5050)
Illness duration (weeks) 1–2 90 24 (11; 48)**** 63 540 (270; 1200)** 133 750 (420; 1400) 162 2625 (1510; 5050)
3–4 153 24 (9; 52) 153 596 (500; 780) 144 800 (400; 1400) 140 2400 (1325; 4610)
5–11 120 38 (17; 64) 129 600 (540; 950) 91 800 (400; 1440) 131 2850 (1350; 4890)
≥12 137 24 (11; 72) 271 640 (560; 976) 118 700 (500; 1220) 153 2480 (1550; 4750)
Cough duration (weeks) 1–2 95 24 (11; 48)**** 80 565 (300; 1148)** 165 800 (400; 1500) 196 2650 (1455; 5100)
3–4 160 24 (9; 50) 169 600 (500; 800) 134 740 (400; 1380) 132 2450 (1450; 4725)
5–11 115 36 (16; 64) 130 630 (540; 1020) 84 800 (490; 1440) 118 2425 (1250; 4750)
≥12 128 24 (11.5; 72) 238 623 (580; 900) 104 700 (500; 1370) 138 2515 (1610; 4750)
Employment status Working 234 24 (10; 56) 202 598 (500; 780)** 367 700 (400; 1300)** 163 2150 (1090; 4050)**
Not working 268 28 (11.5; 63) 417 640 (540; 900) 130 1000 (520; 1600) 436 2650 (1580; 5100)
Occupation Farmer 125 52 (24; 80)* 133 648 (552; 980) 32 800 (535; 1600)*** 140 3375 (2000; 6050)*
Student 47 24 (11; 52) 66 640 (500; 900) 46 1150 (550; 1900) 58 2250 (1250; 4050)
Housewife 121 42 (24; 73) 146 611.5 (500; 848) 22 690 (400; 1040) 210 2850 (1650; 6050)
Labourer 38 11 (5; 21) 21 600 (480; 1080) 21 1200 (640; 1440) 71 2050 (1120; 3250)
Merchant 32 22.5 (8; 52) 97 600 (536; 720) 1 20000 (−; −) 8 1925 (975; 2950)
Government 45 13 (7; 27) 33 600 (540; 700) 86 720 (400; 1300) 61 2500 (1250; 4250)
Other 92 16 (8; 27.5) 117 600 (500; 975) 289 700 (400; 1320) 51 1300 (800; 2950)
aValues are medians and 25–75 % interquartile ranges (IQR) and given in the local currency, unless specified otherwise
*P <0.001, **P < 0.01, ***P < 0.05, ****P < 0.2
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share minibuses or taxis to move from the slums sur-
rounding the metropolitan areas. Although transport
costs were incurred for different reasons in each loca-
tion, they represented more than half of patient expend-
iture to attend diagnostic centres and are thus a major
barrier. Addressing these issues would require long term
infrastructural development. However interim solutions
such as recruiting community volunteers or community
workers to organise transport and the provision of sup-
port funds that facilitate transport could be explored
[21]. Similar issues occur for other diseases such as
HIV/AIDS, the management of accidents and emergen-
cies and complicated deliveries.
A high proportion of patients attended with company in
all study settings. This was especially prominent in Yemen,
where 4 out of 5 patients came accompanied, and signifi-
cantly increased the costs associated with displacement. In
Yemen, gender norms meant that women in particular
were required to be accompanied by a male relative and
faced particular challenges in accessing a TB diagnosis [20].
The need for company also reflects cultural practices
underpinning support to a person perceived to have a mor-
tal illness - in Ethiopia, for example, TB is equated with
lung cancer - and the frailty of patients with chronic and
debilitating conditions. Rural residents were more likely to
attend with company in all countries, which is probably
the reason why these patients had higher expenditure in
Ethiopia and Yemen than patients from urban areas [11].
Our findings indicate that despite the differences in
the settings, patients across LMICs experience many
similarities in the type of costs associated with clinic at-
tendance and that it might be feasible to identify patients
at risk of high expenditure by conducting a simple
questionnaire when they present to diagnostic centres.
This is particularly relevant in the context of the Global
Plan to Stop TB 2016–2020, which aims to eliminate the
number of families facing catastrophic costs due to TB
[1, 22]. In the study context, additional support made
available by NTPs could be channelled to those most at
risk of high costs, including illiterate patients, those ori-
ginating from rural areas or attending with company.
This approach could also reimburse expenses to all pa-
tients investigated for TB; independently of whether the
diagnosis is confirmed.
This analysis, however, has several limitations, beginning
with the sampling strategy, which carried a risk of selection
bias. Participants were recruited using systematic random
sampling, rather than randomly, as this suited the objec-
tives of the larger clinical trial [14]. Patients arriving at the
beginning of the day might have had different characteris-
tics from those arriving later. We can hypothesise that the
former might have resided more locally, or conversely,
have travelled the previous day from afar and stayed over-
night. Patients arriving early might have been better pre-
pared. Next, second day costs were calculated according to
patients’ predicted expenses, rather than the actual costs
incurred. Moreover, all costs were self-reported, rather
than observed by investigators. Actual and predicted ex-
penditure might have been expressed differently by differ-
ent subgroups of the population and different cultures, as
mediated by established social hierarchies, gender roles,
economic standing and the distribution of power, to name
but a few modifiers. For example, costs which might be
overstated by patients in one setting in the hope of finan-
cial remuneration might be underreported in another out
of individual pride. Women who do not have access to
Table 5 Risk factors for high patient expenditure, odds ratios (OR), adjusted odds ratios (AOR) with 95 % Confidence intervals (95 % CI)
by country
Ethiopia Nepal Nigeria Yemen
Variable OR AOR OR AOR OR AOR OR AOR
Age ≥50 1.1 (0.6–1.8) 1.3 (0.9–1.8) 1.6 (0.8–3.2) 1.3 (0.9–1.9)
Male 0.9 (0.6–1.4) 1.4 (0.9–2.1) 2.0 (1.3–3.2) 1.1 (0.7–1.6) 0.7 (0.5–1.1)
Married or with partner 1.9 (1.3–3.0) 0.8 (0.5–1.3) 1.0 (0.7–1.5) 1.1 (0.7–1.7)
Rural/other town residency 23.6 (10.2–55) 15.3 (6.5–36.0) 1.5 (1.0–2.2) 1.1 (0.6–1.8) 6.9 (4.2–11.3) 6.7 (4.1–11.0)
Illiterate 1.9 (1.3–2.9) 1.7 (1.1–2.6) 2.5 (1.5–4.0) 2.4 (1.4–4.3) 1.9 (1.0–3.4) 1.7 (1.2–2.5)
Education nil or primary 2.5 (1.3–4.8) 1.4 (1.0–2.1) 1.1 (0.7–1.7) 1.9 (1.1–3.3)
Accompanied 19.7 (6.1, 63) 7.5 (2.3–25.2) 1.5 (1.0–2.2) 2.7 (1.8–4.2) 2.5 (1.6–3.9) 3.4 (1.7–7.0) 3.1 (1.5–6.5)
Smear-positive 0.9 (0.5–1.4) 2.2 (1.3–3.7) 0.8 (0.5–1.5) 1.0 (0.6–1.5)
Culture-positive 1.0 (0.6–1.6) 2.2 (1.3–3.7) 2.3 (1.3–3.8) 1.0 (0.6–1.7) 0.9 (0.6–1.4)
Illness≥ 12 weeks 1.6 (1.0–2.4) 1.2 (0.8–1.7) 0.9 (0.5–1.5) 0.9 (0.6–1.5)
Cough≥ 5 to 11 weeks 1.3 (0.8–2.0) 1.3 (0.9–2.1) 1.2 (0.7–2.0) 1.0 (0.6–1.6)
Not working 1.2 (0.8–1.9) 1.1 (0.8–1.7) 1.7 (1.1–2.7) 1.4 (0.9–2.1)
Farmer, student,
housewife, labourer
3.8 (2.2–6.5) 1.1 (0.8–1.6) 1.4 (0.9–2.3) 2.3 (1.3–4.0)
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household finances might also be unaware of the full cost
of attendance. Calculation of costs as a proportion of indi-
vidual income would have provided a more complete pic-
ture of the economic burden for the individual and their
family, however including the many variables involved in
these calculations was not possible within the confines of
a short addition to a large survey and asking participants
to disclose their income was considered unreliable.
The costs described here represent only a proportion of
the economic barriers faced by individuals with symptoms
of TB, as the cost of previous healthcare, visits to the pri-
vate sector and indirect costs - such as loss of employment
and work time – which may constitute a major part of pa-
tients’ outgoings, were not documented [19, 20, 23–26].
Opportunity costs tend to be higher for people living in
poverty, who for the most part work in the informal sector
and are vulnerable to loss of income or dismissal from
work [27]. In countries with high HIV prevalence, this vul-
nerability is heightened, as the population perceives that
patients with TB are likely to be co-infected with HIV [28].
Furthermore, a large proportion of symptomatic adults do
not attend diagnostic centres and these individuals often
have fewer financial and social resources at their disposal
[20]. Financial barriers could be alleviated at the point of
care through further decentralisation of health services
[29], the provision of free diagnostic services, transport for
remote populations and/or mobilisation of services to re-
mote communities [28, 30, 31].
Conclusion
The costs incurred by patients are substantial and share
common patterns across countries. Removing user fees,
transparent charging policies and reimbursing clinic ex-
penses would reduce the poverty-inducing effects of direct
diagnostic costs. In locations with limited resources, sup-
port could be prioritised for those most at risk of high ex-
penditure; those who are illiterate, attend the service with
company and rural residents.
Poverty constitutes a major access barrier for symptom-
atic adults in low income countries, as recently recognised
by the Sustainable Development Goals (SMGs) [32]. Pov-
erty is often compounded by low education and health in-
formation, leading to misconceptions of the disease and
disempowerment. Rural and urban residence also deter-
mines access to diagnostic services. Addressing poverty is
likely to be the most crucial factor in determining the suc-
cess or failure of the Global Health Plan to Stop TB 2016–
2020 as a significant public health problem [1] and recog-
nised as major impediment for the achievement of the TB
component of the SMGs [17, 33].
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